Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT01846390 Completed - Clinical trials for Diffuse Large B-Cell Lymphoma

Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

Start date: October 1, 2013
Phase: Phase 1
Study type: Interventional

This research is being done because it is not yet known what dose of romidepsin in combination with gemcitabine, dexamethasone, and cisplatin (GDP) can be given safely to patients with peripheral T-cell lymphoma, nor what type and severity of side effects will result from the combination of these treatments. This research is also being done because it is not clear if the addition of the new drug romidepsin to treatment with GDP can offer better results and longer survival.

NCT ID: NCT01844583 Completed - Lymphoma Clinical Trials

Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

Start date: June 25, 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the drug-drug interaction (DDI) of either esomeprazole or rifampin on the single-dose PK of alisertib, and to complete an intensive QT study of single and multiple-dose alisertib.

NCT ID: NCT01843998 Withdrawn - Clinical trials for Cutaneous T-cell Lymphoma (CTCL)

Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)

Start date: February 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether sirolimus reduces the symptoms of cutaneous T-cell lymphoma (CTCL) and whether it causes any side effects.

NCT ID: NCT01843868 Not yet recruiting - Clinical trials for Lymphoma, Non-Hodgkin

Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP

Start date: May 2013
Phase: N/A
Study type: Interventional

The incidence and severity of chemotherapy-induced nausea and vomiting (CINV) in patients receiving R-CHOP chemotherapy for in non-Hodgkin's lymphoma is not well documented. The contribution of prednisolone to CINV control in the R-CHOP regimen is also unclear. This study aims to evaluate the overall effectiveness of antiemetic control using a standardised 5HT3 (5-Hydroxytryptamine 3) antagonist-containing regimen (e.g. ondansetron) in a heterogeneous group of patients receiving R-CHOP chemotherapy (Rituximab Doxorubicin Vincristine Cyclophosphamide Prednisolone).

NCT ID: NCT01842672 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia

MITCL
Start date: March 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The combination of mitoxantrone and clofarabine as reinduction therapy will be safe, well tolerated and effective in children, adolescents and young adults with poor risk refractory/relapsed acute leukemia and high grade non-Hodgkin lymphoma (NHL).

NCT ID: NCT01841814 Withdrawn - Lymphoma Clinical Trials

Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy

LYMPHOS
Start date: April 2013
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess changes of bone mineral density (BMD) at 12 months during the therapeutic management of patients with lymphoma.

NCT ID: NCT01841021 Terminated - Clinical trials for Peripheral T-Cell Lymphoma

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

Start date: April 2014
Phase: N/A
Study type: Interventional

The main purpose of this study is to test if brentuximab vedotin has an effect on cancer in patients with a certain type of large B-cell lymphoma. The side effects (unwanted effects) of SGN-35 in patients with this certain type of large B-cell lymphoma will also be studied. It is not known if brentuximab vedotin is better or worse than other treatment patients might be given.

NCT ID: NCT01840566 Active, not recruiting - Clinical trials for Non-Hodgkin's Lymphoma

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Start date: April 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety of delivering the patients' own immune cells, called T cells, after the high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT).

NCT ID: NCT01839916 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Start date: April 4, 2013
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies how well giving donor T cells after donor stem cell transplant works in treating patients with hematologic malignancies. In a donor stem cell transplant, the donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect.

NCT ID: NCT01839097 Completed - Clinical trials for Peripheral T-cell Lymphoma

Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)

Start date: May 2013
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to determine the Maximum Tolerated Dose (MTD) for belinostat when combined with CHOP regimen and establish the recommended belinostat dose for the Phase 3 study.